Search

Your search keyword '"Trippa, F"' showing total 192 results
Start Over Author "Trippa, F"
192 results on '"Trippa, F"'

3. STereotactic Ablative RadioTherapy in NEWly Diagnosed and Recurrent Locally Advanced Non-Small Cell Lung Cancer Patients Unfit for ConcurrEnt RAdio-Chemotherapy: Early Analysis of the START-NEW-ERA Non-Randomised Phase II Trial

Author

Arcidiacono, F., Anselmo, P., Casale, M., Zannori, C., Ragusa, M., Mancioli, F., Marchetti, G., Loreti, F., Italiani, M., Bracarda, S., Maranzano, E., and Trippa, F.

Subjects
Cancer Research, Radiation, Oncology, Radiology, Nuclear Medicine and imaging
Abstract

This is a single arm phase 2 trial (Clinical trials.gov NCT05291780) to assess local control (LC) and safety of SAbR in patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC) unfit for concurrent chemo-radiation therapy (ChT-RT).Neoadjuvant ChT was prescribed in fit patients. The tumor volume included primary tumor and any regionally positive node/s. The coprimary study endpoints were LC and safety.Between December 31, 2015, and December 31, 2020, 50 patients with LA-NSCLC were enrolled. Histology was squamous cell carcinoma and adenocarcinoma (ADC) in 52% and 48%, respectively. Forty (80%) patients had ultracentral tumor. Twenty-seven (54%) received neoadjuvant ChT and 7 (14%) adjuvant durvalumab. Median prescribed dose was 45 Gy (range, 35-55) and 40 Gy (35-45) in 5 daily fractions to tumor and node/s, respectively. After a median follow-up of 38 months (range, 12-80), 19 (38%) patients had experienced local recurrence (LR) at a median time of 13 months (range, 7-34). The median LR-free survival (FS) was not reached (95% confidence interval [CI], 28 to not reached). The 1-, 2-, and 3-year LR-FS rates were 86% ± 5%, 66% ± 7%, and 56% ± 8%, respectively. At last follow-up, 33 (66%) patients were alive. Median overall survival (OS) was 55 months (95% CI, 43-55 months). The 1-, 2-, and 3-year OS rates were 94% ± 3%, 79% ± 6%, and 72% ± 7%, respectively. No patients developed ≥ grade (G) 3 toxicity. ADC (hazard ratio [HR], 3.61; 95% CI, 1.15-11.35) was a significant predictor of better LC, while OS was significantly conditioned by smaller planning target volumes (HR, 1.004; 95% CI, 1.001-1.010) and tumor, node, and metastasis stage (HR, 4.8; 95% CI, 1.34-17).Patients with LA-NSCLC treated with SABR had optimal LC and promising OS in absence of ≥G3 toxicity. Our early outcomes would suggest the feasibility of using this approach in patients with LA-NSCLC unfit for concurrent ChT-RT.

Published
2023

6. OC-0763 SAbR in LA-NSCLC patients unfit for concurrent ChT-RT: START-NEW-ERA non-randomised phase II trial

Author

Arcidiacono, F., primary, Anselmo, P., additional, Casale, M., additional, Zannori, C., additional, Loreti, F., additional, Ragusa, M., additional, Enrico, B., additional, Mancioli, F., additional, Marchetti, G., additional, Italiani, M., additional, Fabiani, S., additional, Guida, A., additional, Tassi, V., additional, Caprera, C., additional, Corsi, M., additional, Bracarda, S., additional, Maranzano, E., additional, and Trippa, F., additional

Published
2023
Full Text
View/download PDF

9. 19 A large, multicenter, retrospective study on efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic ovarian cancer (MITO RT1 study)

Author

Macchia, G, Lazzari, R, Colombo, N, Laliscia, C, Capelli, G, D’Agostino, GR, Deodato, F, Trippa, F, Ippolito, E, Ronchi, S, Pajar, F, Scorsetti, M, Cilla, S, Ingargiola, R, Huscher, A, Cerrotta, AM, Andrei, F, Vicenzi, L, Russo, D, Borghesi, S, Perrucci, E, Pignata, S, Aristei, C, Morganti, AG, Scambia, G, Valentini, V, Jereczek-Fossa, BA, and Ferrandina, G

Published
2019
Full Text
View/download PDF

10. Salvage Radiotherapy Guided by Functional Imaging for Macroscopic Local Recurrence Following Radical Prostatectomy: A Multicentric Retrospective Study

Author

Benziane-Ouaritini, N., primary, Zilli, T., additional, Ingrosso, G., additional, di Staso, M., additional, Trippa, F., additional, Francolini, G., additional, Meyer, E., additional, Achard, V.M., additional, Schick, U., additional, Cosset, J.M., additional, Martin, E., additional, Penna, R. Renard, additional, Ferrari, V., additional, Giraud, N., additional, Pasquier, C., additional, Magne, N., additional, Anger, E., additional, Aristei, C., additional, Perrenec, T., additional, Gnep, K., additional, Pasquier, D., additional, Supiot, S., additional, Sargos, P., additional, and Latorzeff, I., additional

Published
2022
Full Text
View/download PDF

14. OC-0607 Radiotherapy guided by functional imaging for macroscopic local recurrence following prostatectomy

Author

Benziane, N., primary, Sargos, P., additional, Zilli, T., additional, Giraud, A., additional, Ingrosso, G., additional, Di Staso, M., additional, Trippa, F., additional, Meyer, E., additional, Francolini, G., additional, Schick, U., additional, Cosset, J.M., additional, Martin, E., additional, Ferrari, V., additional, Achard, V., additional, Giraud, N., additional, Pasquier, C., additional, Magné, N., additional, Pasquier, D., additional, Supiot, S., additional, Latorzeff, I., additional, Gnep, K., additional, Pommier, P., additional, Perennec, T., additional, and Zaine, H., additional

Published
2022
Full Text
View/download PDF

16. Stereotactic radiotherapy for oligometastases in the lymph nodes

Author

Pasqualetti, F., Trippa, F., Aristei, C., Borghesi, S., Colosimo, C., Cantarella, M., Mazzola, R., and Ingrosso, G.

Subjects
Oligometastasis, Toxicity, Oncology, Local control, Stereotactic radiotherapy, Hypofractionation, Radiology, Nuclear Medicine and imaging, Bed, Organ motion, Radiosurgery, Lymph node metastases
Abstract

Even though systemic therapy is standard treatment for lymph node metastases, metastasis-directed stereotactic radiotherapy (SRT ) seems to be a valid option in oligometastatic patients with a low disease burden. Positron emission tomography-computed tomography (PET-CT ) is the gold standard for assessing metastases to the lymph nodes; co-registration of PET-CT images and planning CT images are the basis for gross tumor volume (GTV ) delineation. Appropriate techniques are needed to overcome target motion. SRT schedules depend on the irradiation site, target volume and dose constraints to the organs at risk (OARs) of toxicity. Although several fractionation schemes were reported, total doses of 48-60 Gy in 4-8 fractions were proposed for mediastinal lymph node SRT, with the spinal cord, esophagus, heart and proximal bronchial tree being the dose limiting OAR s. Total doses ranged from 30 to 45 Gy, with daily fractions of 7-12 Gy for abdominal lymph nodes, with dose limiting OARs being the liver, kidneys, bowel and bladder. SRT on lymph node metastases is safe; late side effects, particularly severe, are rare.

Published
2021

20. 126P Chemotherapy and stereotactic ablative radiotherapy in newly diagnosed and recurrent locally advanced non-small cell lung cancer patients unfit for concurrent radiochemotherapy: Sub-analysis and update of START-NEW-ERA non-randomised phase II trial

Author

Arcidiacono, F., Anselmo, P., Casale, M., Zannori, C., Loreti, F., Italiani, M., Enrico, B., Fabiani, S., Marchetti, G., Tassi, V., Mancioli, F.A., Muti, M., Guida, A., Bracarda, S., Ragusa, M., Maranzano, E., and Trippa, F.

Published
2023
Full Text
View/download PDF

23. PH-0118: Stereotactic or conventional RT for macroscopic prostate bed recurrence: a propensity score analysis

Author

Francolini, G., primary, Jereczek-Fossa, B.A., additional, Di Cataldo, V., additional, Simontacchi, G., additional, Marvaso, G., additional, Zerella, M.A., additional, Gentile, P., additional, Bianciardi, F., additional, Allegretta, S., additional, Detti, B., additional, Masi, L., additional, Ciccone, L.P., additional, Bruni, A., additional, Ingrosso, G., additional, Mazzeo, E., additional, Trippa, F., additional, Lohr, F., additional, and Livi, L., additional

Published
2020
Full Text
View/download PDF

24. Imaging targeted treatments versus extended salvage lymph node dissection for patients with a single nodal recurrence of prostate cancer: A comparative analysis from a large multi-institutional series

Author

Cannoletta, C., primary, Fossati, N., additional, Karnes, R., additional, Heidenreich, A., additional, Stief, C., additional, Battaglia, A., additional, Joniau, S., additional, Osmonov, D., additional, Shariat, S., additional, Albers, P., additional, Tilki, D., additional, Gill, I., additional, Mottrie, A., additional, Jereczek-Fossa, B., additional, Pasquier, D., additional, Zilli, T., additional, Van As, N., additional, Siva, S., additional, Fodor, A., additional, Dirix, P., additional, De Iturriaga, A., additional, Trippa, F., additional, Detti, B., additional, and Ost, P., additional

Published
2019
Full Text
View/download PDF

25. 19 A large, multicenter, retrospective study on efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic ovarian cancer (MITO RT1 study)

Author

Macchia, G, primary, Lazzari, R, additional, Colombo, N, additional, Laliscia, C, additional, Capelli, G, additional, D’Agostino, GR, additional, Deodato, F, additional, Trippa, F, additional, Ippolito, E, additional, Ronchi, S, additional, Pajar, F, additional, Scorsetti, M, additional, Cilla, S, additional, Ingargiola, R, additional, Huscher, A, additional, Cerrotta, AM, additional, Andrei, F, additional, Vicenzi, L, additional, Russo, D, additional, Borghesi, S, additional, Perrucci, E, additional, Pignata, S, additional, Aristei, C, additional, Morganti, AG, additional, Scambia, G, additional, Valentini, V, additional, Jereczek-Fossa, BA, additional, and Ferrandina, G, additional

Published
2019
Full Text
View/download PDF

32. Imaging targeted treatments versus extended salvage lymph node dissection for patients with a single nodal recurrence of prostate cancer: A comparative analysis from a large multi-institutional series

Author

Fossati, N., primary, Karnes, R.J., additional, Heidenreich, A., additional, Stief, C., additional, Battaglia, A., additional, Joniau, S., additional, Osmonov, D., additional, Shariat, S., additional, Albers, P., additional, Tilki, D., additional, Gill, I.S., additional, Mottrie, A., additional, Jereczek-Fossa, B.A., additional, Pasquier, D., additional, Zilli, T., additional, Van As, N., additional, Siva, S., additional, Fodor, A., additional, Dirix, P., additional, De Iturriaga, A.G., additional, Trippa, F., additional, Detti, B., additional, and Ost, P., additional

Published
2019
Full Text
View/download PDF

33. Comparing stereotactic body radiotherapy and elective nodal radiotherapy in the management of nodal oligorecurrent prostate cancer: A multi-institutional analysis

Author

De Bleser, E., primary, Jereczek-Fossa, B.A., additional, Pasquier, D., additional, Zilli, T., additional, Van As, N., additional, Siva, S., additional, Fodor, A., additional, Dirix, P., additional, Gomez De Iturriaga, A., additional, Trippa, F., additional, Detti, B., additional, Ingrosso, G., additional, Triggiani, L., additional, Alessio, B., additional, Alongi, F., additional, Reynders, D., additional, Fonteyne, V., additional, Surgo, A., additional, Loukili, K., additional, Miralbell, R., additional, Silva, P., additional, Chander, S., additional, Goetghebeur, E., additional, and Ost, P., additional

Published
2019
Full Text
View/download PDF

34. Comparing stereotactic body radiotherapy and elective nodal radiotherapy in the management of nodal oligorecurrent prostate cancer: a multi-institutional analysis

Author

De Bleser, E., primary, Jereczek-Fossa, B.A., additional, Pasquier, D., additional, Zilli, T., additional, Van As, N., additional, Siva, S., additional, Fodor, A., additional, Dirix, P., additional, Gomez De Iturriaga, A., additional, Trippa, F., additional, Detti, B., additional, Ingrosso, G., additional, Triggiani, L., additional, Alessio, B., additional, Alongi, F., additional, Fonteyne, V., additional, Surgo, A., additional, Loukili, K., additional, Miralbell, R., additional, Pedro, S., additional, Chander, S., additional, Di Muzio, N.G., additional, Francolini, G., additional, Lancia, A., additional, Tree, A., additional, and Ost, P., additional

Published
2018
Full Text
View/download PDF

35. A prospective observational trial on emesis in radiotherapy: Analysis of 1020 patients recruited in 45 Italian radiation oncology centres

Author

Maranzano, E, DE ANGELIS, V, Pergolizzi, S, Lupattelli, M, Frata, Paolo, Spagnesi, S, Frisio, Ml, Mandoliti, G, Malinverni, G, Trippa, F, Fabbietti, L, Parisi, S, DI PALMA, A, DE VECCHI, P, DE RENZIS, C, Giorgetti, C, Bergami, T, Orecchia, R, Portaluri, M, Signor, M, DI GENNARO, D, and THE ITALIAN GROUP FOR ANTIEMETIC RESEARCH IN RADIOTHERAPY

Subjects
Male, medicine.medical_specialty, Vomiting, Nausea, medicine.drug_class, medicine.medical_treatment, Risk Factors, Internal medicine, medicine, Humans, Antiemetic, Radiology, Nuclear Medicine and imaging, Prospective Studies, Chemotherapy, Radiotherapy, business.industry, Incidence, Incidence (epidemiology), Hematology, Middle Aged, Radiation therapy, Italy, Oncology, Anesthesia, Concomitant, Antiemetics, Female, Observational study, medicine.symptom, business
Abstract

Purpose A prospective observational multicentre trial was carried out to assess the incidence, pattern, and prognostic factors of radiation-induced emesis (RIE), and to evaluate the use of antiemetic drugs in patients treated with radiotherapy or concomitant radio-chemotherapy. The application in clinical practice of the Multinational Association of Supportive Care in Cancer guidelines was also studied. Materials and methods Forty-five Italian radiation oncology centres took part in this trial. The accrual lasted for 3 consecutive weeks and only patients starting radiotherapy or concomitant radio-chemotherapy in this period were enrolled. Evaluation was based on diary card filled in daily by patients during treatment and one week after stopping it. Diary card recorded the intensity of nausea/vomiting and prophylactic/symptomatic antiemetic drug prescriptions. Results A total of 1020 patients entered into the trial, and 1004 were evaluable. Vomiting and nausea occurred in 11.0% and 27.1% of patients, respectively, and 27.9% patients had both vomiting and nausea. In multifactorial analysis, the only statistically significant patient-related risk factors were concomitant chemotherapy and previous experience of vomiting induced by chemotherapy. Moreover, two radiotherapy-related factors were significant risk factors for RIE, the irradiated site (upper abdomen) and field size (>400 cm2). An antiemetic drug was given only to a minority (17%) of patients receiving RT, and the prescriptions were prophylactic in 12.4% and symptomatic in 4.6%. Different compounds and a wide range of doses and schedules were used. Conclusions These data were similar to those registered in our previous observational trial, and the radiation oncologists’ attitude in underestimating RIE and under prescribing antiemetics was confirmed.

Published
2010

38. SC189 - Imaging targeted treatments versus extended salvage lymph node dissection for patients with a single nodal recurrence of prostate cancer: A comparative analysis from a large multi-institutional series

Author

Cannoletta, C., Fossati, N., Karnes, R., Heidenreich, A., Stief, C., Battaglia, A., Joniau, S., Osmonov, D., Shariat, S., Albers, P., Tilki, D., Gill, I., Mottrie, A., Jereczek-Fossa, B., Pasquier, D., Zilli, T., Van As, N., Siva, S., Fodor, A., Dirix, P., De Iturriaga, A., Trippa, F., Detti, B., and Ost, P.

Published
2019
Full Text
View/download PDF

39. 772 - Imaging targeted treatments versus extended salvage lymph node dissection for patients with a single nodal recurrence of prostate cancer: A comparative analysis from a large multi-institutional series

Author

Fossati, N., Karnes, R.J., Heidenreich, A., Stief, C., Battaglia, A., Joniau, S., Osmonov, D., Shariat, S., Albers, P., Tilki, D., Gill, I.S., Mottrie, A., Jereczek-Fossa, B.A., Pasquier, D., Zilli, T., Van As, N., Siva, S., Fodor, A., Dirix, P., De Iturriaga, A.G., Trippa, F., Detti, B., and Ost, P.

Published
2019
Full Text
View/download PDF

40. 771 - Comparing stereotactic body radiotherapy and elective nodal radiotherapy in the management of nodal oligorecurrent prostate cancer: A multi-institutional analysis

Author

De Bleser, E., Jereczek-Fossa, B.A., Pasquier, D., Zilli, T., Van As, N., Siva, S., Fodor, A., Dirix, P., Gomez De Iturriaga, A., Trippa, F., Detti, B., Ingrosso, G., Triggiani, L., Alessio, B., Alongi, F., Reynders, D., Fonteyne, V., Surgo, A., Loukili, K., Miralbell, R., Silva, P., Chander, S., Goetghebeur, E., and Ost, P.

Published
2019
Full Text
View/download PDF

46. Linee guida per la gestione dei pazienti affetti da melanoma cutaneo

Author

Anselmo, P., Ansidei, Vincenzo, Arcangeli, F., Bartolucci, R., Bini, P., Cartaginese, F., Caserta, C., Cencetti, F., Cordellini, M., Corgna, E., Covarelli, Piero, DEL SORDO, Rachele, Dottorini, M. E., Farabi, R., Fatigoni, S., Francucci, M., Frattegiani, A., Lisi, Paolo, Lolli, G., Loreti, F., Maranzano, E., Mecarocci, D., Messina, Salvatore, Monico, S., Noya, Giuseppe, Papini, Manuela, Porrozzi, S., Roila, F., Rossetti, R., Sidoni, Angelo, Simonetti, S., Tagliaventi, M., Tomassini, G. M., and Trippa, F.

Published
2011

47. 'Hypofractionated radiotherapy in'

Author

Lupatelli, M, Amelio, D, Anselmo, P, Scoccianti, S, Beneventi, S, Bellavita, R, Bagnoli, R, Trippa, F, Mirri, Ma, Magrini, Stefano Maria, Checcaglini, F, and Aristei, C.

Published
2008

49. La palliazione in radioterapia oncologica

Author

Aglietta, M, Anselmo, P, AUSILI-CEFARO, G, Basagni, Ml, Brandes, Aa, Buffoli, A, Cellini, N, Chirico, L, Conforti, F, Corvo', R, Costantini, S, Donato, V, Ferrara, T, Franceschi, E, Fiusco, V, Gabriele, P, Garibaldi, E, Gava, A, Genovesi, D, Ippolito, E, Lazzari, G, Livi, L, Luca', F, Lupattelli, M, Magnani, K, Malinverni, G, Mandoliti, G, Manzo, R, Marangolo, M, Mattiucci, Gc, Maranzano, E, Marmiroli, L, Mazzarotto, R, Monaco, A, Muto, P, Paiar, F, Paoletti, L, Pergolizzi, S, Rossi, R, Sacco, S, Scopa, A, Signor, A, Signor, M, Silvano, G, Soffietti, R, Sotti, G, Toniolo, E, Trevisan, E, Trippa, F, Turriziani, A, Vagge, S, Valentini, V, Vianello, F, and Zorat, Pl

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results